CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Does the media favor CASI or ANRO?

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Alto Neuroscience. CASI Pharmaceuticals' average media sentiment score of 1.89 beat Alto Neuroscience's score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CASI Pharmaceuticals	Very Positive
Alto Neuroscience	Neutral

Which has more volatility & risk, CASI or ANRO?

CASI Pharmaceuticals has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Is CASI or ANRO more profitable?

Alto Neuroscience has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Alto Neuroscience's return on equity of -39.35% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-129.05%	-972.55%	-77.33%
Alto Neuroscience	N/A	-39.35%	-33.86%

Do analysts recommend CASI or ANRO?

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 190.91%. Alto Neuroscience has a consensus target price of $8.50, suggesting a potential upside of 228.82%. Given Alto Neuroscience's higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alto Neuroscience	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Do insiders and institutionals have more ownership in CASI or ANRO?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings & valuation, CASI or ANRO?

CASI Pharmaceuticals has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$31.37M	0.54	-$39.26M	-$2.55	-0.54
Alto Neuroscience	N/A	N/A	-$61.43M	-$2.34	-1.10

Summary

CASI Pharmaceuticals beats Alto Neuroscience on 8 of the 15 factors compared between the two stocks.